Amphera progresses two pancreatic cancer programmes after encouraging initial safety and efficacy data in mesothelioma

Proof-of-concept Phase I clinical trial started to assess the safety and efficacy of CD40 agonist mitazalimab in combination with MesoPher in patients with progressive metastatic pancreatic cancer

DC vaccination-αCD40 combination therapy improves survival of pancreatic tumour-bearing mice

DENIM study presented at IMIG2021

Amphera recruits first patients to phase II study of MesoPher to treat pancreatic cancer

Amphera wins top ten list of most groundbreaking innovations in science

Amphera presents data of MesoPher and checkpoint inhibitor combination therapy to treat mesothelioma at AACR 2019